强化血糖控制对不同心血管风险及糖化血红蛋白水平的2型糖尿病患者临床结局的影响:ADVANCE试验
在ADVANCE试验11,071例2型糖尿病患者中,强化血糖控制较标准治疗降低主要血管事件(HR 0.90,95%CI 0.83-0.98),但增加严重低血糖风险(HR 1.85,95%CI 1.41-2.42);上述效应在基线ASCVD风险或HbA1c不同水平间无显著异质性。
要点
- 强化血糖控制降低主要血管事件(HR 0.90,95%CI 0.83-0.98),主要驱动为减少大量白蛋白尿。
- 强化血糖控制增加严重低血糖风险(HR 1.85,95%CI 1.41-2.42)。
- 获益与风险在基线ASCVD风险或HbA1c不同水平间无显著异质性。
核心结论
- ADVANCE试验中2型糖尿病患者的主要获益在基线ASCVD风险和HbA1c不同水平间无实质差异。
- 强化血糖控制降低主要血管事件(HR 0.90,95%CI 0.83-0.98),主要驱动为减少大量白蛋白尿。
- 强化血糖控制增加严重低血糖风险(HR 1.85,95%CI 1.41-2.42)。
研究设计与样本
- 研究为ADVANCE试验的事后分析,纳入11,071例无缺失值的2型糖尿病患者,使用Cox模型评估强化血糖控制的效果。
主要发现
- 中位随访5年期间,强化血糖控制组主要血管事件风险较标准血糖控制组降低(HR 0.90,95%CI 0.83-0.98)。
- 强化血糖控制对主要血管事件的影响在基线ASCVD风险(交互P=0.29)或HbA1c水平(交互P=0.94)间无显著差异。
- 强化血糖控制对全因死亡的影响在基线ASCVD风险(P=0.15)或HbA1c水平(P=0.87)间无显著差异。
- 强化血糖控制组严重低血糖事件风险较标准血糖控制组升高(HR 1.85,95%CI 1.41-2.42),在基线ASCVD风险(P=0.09)或HbA1c水平(P=0.18)亚组间无显著异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study whether the effects of intensive glycemic control on major vascular outcomes (a composite of major macrovascular and major microvascular events), all-cause mortality, and severe hypoglycemia events differ among participants with different levels of 10-year risk of atherosclerotic cardiovascular disease (ASCVD) and hemoglobin A1c (HbA1c) at baseline. RESEARCH DESIGN AND METHODS: We studied the effects of more intensive glycemic control in 11,071 patients with type 2 diabetes (T2D), without missing values, in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, using Cox models. RESULTS: During 5 years' follow-up, intensive glycemic control reduced major vascular events (hazard ratio [HR] 0.90 [95% CI 0.83-0.98]), with the major driver being a reduction in the development of macroalbuminuria. There was no evidence of differences in the effect, regardless of baseline ASCVD risk or HbA1c level (P for interaction = 0.29 and 0.94, respectively). Similarly, the beneficial effects of intensive glycemic control on all-cause mortality were not significantly different across baseline ASCVD risk (P = 0.15) or HbA1c levels (P = 0.87). The risks of severe hypoglycemic events were higher in the intensive glycemic control group compared with the standard glycemic control group (HR 1.85 [1.41-2.42]), with no significant heterogeneity across subgroups defined by ASCVD risk or HbA1c at baseline (P = 0.09 and 0.18, respectively). CONCLUSIONS: The major benefits for patients with T2D in ADVANCE did not substantially differ across levels of baseline ASCVD risk and HbA1c.
引用
- Tian J, Ohkuma T, Cooper M, et al. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial. Diabetes Care. 2020. PMID: 32193249. doi:10.2337/dc19-1817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。